<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A randomized controlled trial is being conducted in Japan to compare hepatectomy alone with hepatectomy followed by adjuvant chemotherapy as treatment in patients with curatively resected <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to improve survival with intensive chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Between 42 and 70 days after liver resection, patients are randomly assigned to either hepatectomy alone or hepatectomy followed by 12 cycles of modified FOLFOX6 (mFOLFOX6) regimen </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 300 patients (including 78 patients in Phase II) will be accrued from 38 institutions within 3 years </plain></SENT>
<SENT sid="3" pm="."><plain>The primary endpoint is treatment compliance at nine courses of mFOLFOX6 regimen in Phase II and disease-free survival in Phase III </plain></SENT>
<SENT sid="4" pm="."><plain>The secondary endpoints are overall survival, incidence of adverse events and patterns of recurrence </plain></SENT>
</text></document>